Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, single-center, nonrandomized, open-label, active-controlled, 2-period, 2-treatment evaluation of multiple-dose topical administration of FMX-101 minocycline foam 4%, compared to oral administration of Solodyn (minocycline HCl) extended-release tablets in subjects with moderate-to-severe facial acne vulgaris and acne: Bridging/Maximal Use (MUSE) trial

Next Previous
Trial Profile

A Phase 1, single-center, nonrandomized, open-label, active-controlled, 2-period, 2-treatment evaluation of multiple-dose topical administration of FMX-101 minocycline foam 4%, compared to oral administration of Solodyn (minocycline HCl) extended-release tablets in subjects with moderate-to-severe facial acne vulgaris and acne: Bridging/Maximal Use (MUSE) trial

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Jan 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Minocycline (Primary)
  • Indications Acne
  • Focus Pharmacokinetics
  • Acronyms MUSE

    • Most Recent Events

    • 07 Jan 2016 Status changed from active, no longer recruiting to completed, as published in the Media Release
    • 07 Jan 2016 Results published in the Media Release
    • 11 Nov 2015 According to Foamix media release, results are expected to be released during Q4, 2015.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top